146 related articles for article (PubMed ID: 7588234)
1. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo.
Howe SR; Gottardis MM; Everitt JI; Walker C
Endocrinology; 1995 Nov; 136(11):4996-5003. PubMed ID: 7588234
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
3. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.
Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C
Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178
[TBL] [Abstract][Full Text] [Related]
4. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
[TBL] [Abstract][Full Text] [Related]
6. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
7. Regulation of apoptosis in uterine leiomyomata.
Burroughs KD; Kiguchi K; Howe SR; Fuchs-Young R; Trono D; Barrett JC; Walker C
Endocrinology; 1997 Jul; 138(7):3056-64. PubMed ID: 9202252
[TBL] [Abstract][Full Text] [Related]
8. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.
Gottardis MM; Ricchio ME; Satyaswaroop PG; Jordan VC
Cancer Res; 1990 Jun; 50(11):3189-92. PubMed ID: 2334915
[TBL] [Abstract][Full Text] [Related]
9. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
10. Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis.
Howe SR; Everitt JI; Gottardis MM; Walker C
Ann N Y Acad Sci; 1995 Jun; 761():373-5. PubMed ID: 7625739
[No Abstract] [Full Text] [Related]
11. Autocrine regulation of cell proliferation by estradiol and hydroxytamoxifen of transformed mouse Leydig cells in serum-free culture.
Nishizawa Y; Sato B; Miyashita Y; Tsukada S; Hirose T; Kishimoto S; Matsumoto K
Endocrinology; 1988 Jan; 122(1):227-35. PubMed ID: 3275537
[TBL] [Abstract][Full Text] [Related]
12. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
14. Functional and growth properties of a myometrial cell line derived from transgenic mice: effects of estradiol and antiestrogens.
Blin C; L'Horset F; Romagnolo B; Colnot S; Lambert M; Thomasset M; Kahn A; Vandewalle A; Perret C
Endocrinology; 1996 Jun; 137(6):2246-53. PubMed ID: 8641172
[TBL] [Abstract][Full Text] [Related]
15. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
16. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus.
Campen CA; Jordan VC; Gorski J
Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316
[TBL] [Abstract][Full Text] [Related]
17. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line).
Anzai Y; Holinka CF; Kuramoto H; Gurpide E
Cancer Res; 1989 May; 49(9):2362-5. PubMed ID: 2706624
[TBL] [Abstract][Full Text] [Related]
18. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice.
Brünner N; Bronzert D; Vindeløv LL; Rygaard K; Spang-Thomsen M; Lippman ME
Cancer Res; 1989 Mar; 49(6):1515-20. PubMed ID: 2924304
[TBL] [Abstract][Full Text] [Related]
19. Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro.
Hodges LC; Bergerson JS; Hunter DS; Walker CL
Toxicol Sci; 2000 Apr; 54(2):355-64. PubMed ID: 10774817
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
